Scientists at IRB Barcelona and the Joint Programme IRB-BSC have discovered 200 new interactions between proteins that could be related to Alzheimer.
In studies conducted on the fruit fly, researchers at IRB Barcelona headed by ICREA Professor Marco Milán have revealed that organs have the molecular mechanisms to control their proportions. In this process the protein p53 plays a crucial role. The study is published today in the prestigious journal PLoS Biology.
The correct establishment of organ proportions, which occurs during embryonic development, is vital for the proper function of all organisms. Alterations in the mechanisms responsible for these processes cause fatal errors in embryos and even cause their death. In the Renaissance period, Leonardo da Vinci, in his famous picture of the “Vitruvian man...
The protein DOR controls the maturation of adult flies depending on availability of nutrients
The new programme will promote interdisciplinary research and mobility between scientists.
Scientists at IRB Barcelona develop a computational strategy to identify potential protein interaction partners regulated by Aurora A kinase.
Scientists at IRB Barcelona have provided new data on how certain types of aggressive breast cancer bypass tumour suppression mechanisms.
In collaboration with the Barcelona Science Park (PCB), IRB Barcelona will be participating in Science Week, the largest public communications event on science and technology in Spain, which this year reached its 15th series. Coordinated by the “Fundació Catalana per a la Recerca i la Innovació” (FCRI), the programme of activities will be held from 12 to 22 November.
The activities include open days on 16 and 18 November. Entitled “Come and do an express PhD”, through a series of clues visitors will analyse the differences between malignant and benign tumour cells. In this regard, they will visit Eduard Batlle’s lab, the Advanced Digital Microscopy Platform and the “Centro...
The new data base, which includes 1,700 proteins in motion, allows a more efficient design of drugs.
MoDEL holds 30% of human therapeutic targets and the objective is to cover 80% in three years.
The biotech enterprise Omnia Molecular, which operates from the PCB-Santander Bioincubator at the Barcelona Science Park and was founded by IRB Barcelona researcher Lluís Ribas de Pouplana, has closed funding negotiations headed by “Caixa Capital Risc”, the risk capital section of “la Caixa", worth 2.1M€ . This round of funding, which is supported by the Empresa Nacional de Innovación (ENISA), has also involved the founding partners of Omnia Molecular (Lluís Ribas, Juan Gargallo y Eugeni Roure) and the new managerial team, comprised by Raphael Klingmann, who serves as CEO, and Dariusch Mani.
Omnia Molecular is devoted to the discovery and...
Researchers Dario Alessi and Joan Guinovart bring together 150 experts in cancer Metabolism in a Barcelona BioMed Conference, organised by IRB Barcelona and the BBVA Foundation.